7:01 am Alkermes announces positive topline results from pivotal phase 3 study of aripiprazole lauroxil for treatment of schizophrenia; once-monthly injectable schizophrenia medication achieved primary and secondary endpoints at both doses
View todays social media effects on ALKS
View the latest stocks trending across Twitter. Click to view dashboard
See who Alkermes is hiring next, click here to view
